Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Aug;72(8):651-657.
doi: 10.1007/s00105-021-04851-z. Epub 2021 Jul 5.

[Epidemiology, patient quality of life, and treatment costs of hidradenitis suppurativa/acne inversa]

[Article in German]
N Kirsten  1   2 , V Frings  3 , G D Nikolakis  4   5 , D Presser  4   3 , M Goebeler  3 , C C Zouboulis  4   5 , M Augustin  6   4
Affiliations
Review

[Epidemiology, patient quality of life, and treatment costs of hidradenitis suppurativa/acne inversa]

[Article in German]
N Kirsten et al. Hautarzt. 2021 Aug.

Abstract
in English, German

Hidradenitis suppurativa/acne inversa (HS) is associated with numerous and relevant restrictions on the quality of life for those affected and their relatives. The exact prevalence of HS varies significantly across studies, but it is likely to be higher than suggested in previous publications. HS care is associated with high costs for the healthcare system and for those affected. The introduction of biologic therapy has led to additional costs, but also to considerable additional benefits in terms of care. In view of the complexity of diagnostics and therapy, there is a particular need for optimized care concepts in order to reduce the burden on those affected, their relatives and the healthcare system.

Hidradenitis suppurativa (HS)/Acne inversa (AI) geht mit zahlreichen und relevanten Einschränkungen der Lebensqualität für die Betroffenen und ihre Angehörigen einher. Literaturangaben zur Prävalenz der HS variieren erheblich, sie ist jedoch wahrscheinlich höher als in früheren Publikationen angenommen. Die Versorgung der HS geht mit hohen Kosten für das Gesundheitssystem und die Betroffenen einher. Die Einführung der Biologikatherapie hat zu weiteren Kosten, jedoch auch erheblichem Mehrnutzen in der Versorgung geführt. Angesichts der Komplexität von Diagnostik und Therapie besteht ein besonderer Bedarf an optimierten Versorgungskonzepten, um die Last für die Betroffenen, ihre Angehörigen und das Gesundheitssystem zu reduzieren.

Keywords: Biological products; Healthcare system; Prevalence; Relatives; Treatment outcome.

PubMed Disclaimer

References

Literatur

    1. Alavi A, Farzanfar D, Lee RK et al (2018) The contribution of malodour in quality of life of patients with hidradenitis suppurativa. J Cutan Med Surg 22:166–174 - PubMed - DOI
    1. Argyropoulou M, Kanni T, Kyprianou M et al (2019) Cost-savings of adalimumab in hidradenitis suppurativa: a retrospective analysis of a real-world cohort. Br J Dermatol 180:1161–1168 - PubMed - DOI - PMC
    1. Balieva F, Kupfer J, Lien L et al (2017) The burden of common skin diseases assessed with the EQ5D: a European multicentre study in 13 countries. Br J Dermatol 176:1170–1178 - PubMed - DOI
    1. Chernyshov PV, Zouboulis CC, Tomas-Aragones L et al (2021) Quality of life in hidradenitis suppurativa. An update. Int J Environ Res Public Health 18:6131 - PubMed - PMC - DOI
    1. Cosmatos I, Matcho A, Weinstein R et al (2013) Analysis of patient claims data to determine the prevalence of hidradenitis suppurativa in the United States. J Am Acad Dermatol 69:819 - PubMed - DOI - PMC

LinkOut - more resources